News | June 02, 2014

CivaTech Oncology’s Linear Brachytherapy Device Added to AAPM Source Registry

June 2, 2014 — CivaTech Oncology’s flagship product, the CivaString source, has been listed on the Joint American Association of Physicists in Medicine/IROC Houston Registry of Brachytherapy Sources meeting the AAPM Dosimetric Prerequisites. This approval is granted through independent investigations and a thorough review process, affirming the robust dosimetric qualities of CivaString and allowing routine product use without special approvals or IRB clinical trial oversight.

This new method of polymer encapsulation of Palladium 103, a low dose rate source with a half–life of 17 days, enables a linear, homogenous dose profile which is designed to be superior to other products encapsulated in metals. CivaString is currently in use for the treatment of prostate cancer.

Suzanne Babcock, CivaTech Oncology chairman and CEO, said, “We are excited to see that both research and clinical usage suggest potential savings of up to 40 percent fewer needles than traditionally required for seed implants. This can result in reductions in tissue trauma and procedural time.” Other advantages of polymer-based brachytherapy include improvement to image quality, should patients require future diagnostics in the region.

The American Cancer Society estimates that in 2014, 233,000 new cases of prostate cancer will be diagnosed and 29,480 men will die of the disease. It is the second leading cause of cancer death among men in the United States. Most men are concerned about the undesirable side effects that accompany all methods of treating prostate cancer and the polymer-based technology may reduce some of these issues.

For more information:

Related Content

ASTRO Issues Clinical Guideline for Whole Breast Radiation Therapy
News | Radiation Therapy | March 12, 2018
The American Society for Radiation Oncology (ASTRO) today issued a new clinical guideline for the use of whole breast...
MD Anderson and RaySearch Partner to Advance Adaptive Radiation Therapy
News | Treatment Planning | February 26, 2018
The University of Texas MD Anderson Cancer Center and RaySearch Laboratories announced a new strategic alliance with...
Mirada Medical Releases DLCExpert for Radiotherapy Treatment Planning
Technology | Treatment Planning | February 22, 2018
February 22, 2018 — U.K.-based medical imaging software provider Mirada Medical has released DLCExpert, the first com
Mitchell Cancer Institute Selects RayStation for TomoTherapy Planning
News | Treatment Planning | February 16, 2018
The University of South Alabama Mitchell Cancer Institute (MCI) in Mobile, Ala., has selected RayStation as its...
Radiography Education Enrollment Shows Marginal Rise in 2017
News | Radiology Business | February 15, 2018
Directors of radiography educational programs report the number of enrolled students increased slightly in 2017, while...
Varian Acquires Mobius Medical Systems
News | Quality Assurance (QA) | February 06, 2018
February 6, 2018 – Varian announced it has acquired privately-held Mobius Medical Systems, a...
Microbubbles Make Breast Cancer More Susceptible to Radiation Therapy
News | Women's Health | February 01, 2018
February 1, 2018 – Injecting breast cancer with oxygen-filled microbubbles makes tumors three-times more sensitive to
​ITN Celebrates World Cancer Day 2018
News | Radiation Oncology | February 01, 2018
World Cancer Day takes place annually on Feb.
Overlay Init